Share

August 30, 2016; 87 (9 Supplement 2) Article

Pediatric multiple sclerosis

Escalation and emerging treatments

Tanuja Chitnis, Angelo Ghezzi, Barbara Bajer-Kornek, Alexey Boyko, Gavin Giovannoni, Daniela Pohl
First published August 29, 2016, DOI: https://doi.org/10.1212/WNL.0000000000002884
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2649

Share

Article Information

vol. 87 no. 9 Supplement 2 S103-S109
DOI: 
https://doi.org/10.1212/WNL.0000000000002884
PubMed: 
27572854
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received August 19, 2015
  • Accepted in final form February 18, 2016
  • First Published August 29, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Tanuja Chitnis, MD,
    2. Angelo Ghezzi, MD,
    3. Barbara Bajer-Kornek, MD,
    4. Alexey Boyko, DSc,
    5. Gavin Giovannoni, PhD, FRCP and
    6. Daniela Pohl, MD, PhD
  1. Tanuja Chitnis, MD,
    2. Scientific Advisory Boards:

    1. Dr. Chitnis has served on clinical trial advisory boards for Novartis Pharmaceuticals, and Genzyme-Sanofi.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Chitnis has served as a one-time consultant for Biogen-Idec, Novartis, Genzyme-Sanofi and Genentech-Roche.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Chitnis receives research support from (1) EMD-Serono, (2) Novartis, (3) Biogen in the form of Independent Investigator Awards.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dr. Chitnis receives research support from the National Multiple Sclerosis Society, the Peabody Foundation, the Consortium for MS Centers and the Guthy-Jackson Charitable Foundation.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Angelo Ghezzi, MD,
    3. Scientific Advisory Boards:

    1. Merck-Serono, advisory board of a trial in pediatric MS. Biogen, advisory board of a trial in pediatric MS

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Multiple Sclerosis International, no compensation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Merck Serono, speaker in a scientific meeting Biogen Idec, speaker in a scientific meeting Novartis, speaker in a scientific meeting Genzyme, speaker in a scientific meeting Teva, speaker in a scientific meeting

    Consultancies:

    1. Novartis, consulting activity Biogen, consulting activity

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Barbara Bajer-Kornek, MD,
    4. Scientific Advisory Boards:

    1. Bayer-Schering, Genzyme, Merck-Serono, TEVA Aventis, Novartis.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Travel honoraraia and honoraria for speaking from Bayer-Schering, Merck-Serono, TEVA Aventis, Genzyme, Biogen, Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Alexey Boyko, DSc,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Received honorarium as a speaker for Novartis, TEVA, Baeyr\Shcering, Sanofi\Genzyme and others.

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Gavin Giovannoni, PhD, FRCP and
    6. Scientific Advisory Boards:

    1. (1)Biogen-Idec (2) Fiveprime (3) Genzyme (4) GW Pharma (5) Ironwood (6) Merck-Serono (7) Novartis (8) Roche (9) Sanofi-Aventis (10) Synthon BV (11) Teva (12) Vertex Pharmaceuticals (13) Abbvie (14) Canbex

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker honoraria: (1)Biogen-Idec (2) Genzyme (3) GW Pharma (4) Merck-Serono (5) Novartis (6) Roche (7) Teva

    Editorial Boards:

    1. (1) Multiple Sclerosis and Related Disorders, Editor since 2011

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1)Biogen-Idec (2) Fiveprime (3) Genzyme (4) GW Pharma (5) Ironwood (6) Merck-Serono (7) Novartis (8) Roche (9) Sanofi-Aventis (10) Synthon BV (11) Teva (12) Vertex Pharmaceuticals (13) Abbvie (14) Canbex

    Speakers' Bureaus:

    1. (1) Novartis (2) Teva

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Genzyme 2012-2014 Merck 2012-2014

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Daniela Pohl, MD, PhD
    7. Scientific Advisory Boards:

    1. (1) Biogen-Idec (2) Novartis (3) Sanofi (4) Merck-Serono

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) EAN: Funding for travel (2) LACTRIMS: Funding for travel

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From Partners Pediatric MS Center (T.C.), Massachusetts General Hospital, Harvard Medical School, Boston; Divisione di Neurologia 2–Centro Studi Sclerosi Multipla (A.G.), Ospedale di Gallarate, Italy; Department of Neurology (B.B.-K.), Medical University of Vienna, Austria; Department of Neurology, Neurosurgery and Medical Genetics (A.B.), Pirogov's Russian National Research Medical University, Moscow; Barts and The London School of Medicine and Dentistry (G.G.), London, UK; and Department of Neurology (D.P.), Children's Hospital of Eastern Ontario, University of Ottawa, Canada.
  1. Correspondence to Dr. Chitnis: tchitnis{at}partners.org
View Full Text

Article usage

Article usage: August 2016 to March 2023

AbstractFullPdfSource
Aug 20162251045Highwire
Sep 2016878172215Highwire
Oct 20162886082Highwire
Nov 20161806285Highwire
Dec 20161082629Highwire
Jan 20171273050Highwire
Feb 20171762434Highwire
Mar 20171243871Highwire
Apr 20171442540Highwire
May 20171103741Highwire
Jun 2017774139Highwire
Jul 2017932438Highwire
Aug 2017812535Highwire
Sep 20171453751Highwire
Oct 20171112233Highwire
Nov 2017593039Highwire
Dec 201725641Highwire
Jan 201826931Highwire
Feb 2018010637Highwire
Mar 201808136Highwire
Apr 201808545Highwire
May 2018210640Highwire
Jun 201817440Highwire
Jul 201816031Highwire
Aug 201834732Highwire
Sep 201838051Highwire
Oct 201856833Highwire
Nov 201824429Highwire
Dec 201816624Highwire
Jan 2019138133Highwire
Feb 2019116329Highwire
Mar 2019186843Highwire
Apr 2019142718Highwire
May 2019133326Highwire
Jun 2019173437Highwire
Jul 2019292730Highwire
Aug 201972919Highwire
Sep 201924428Highwire
Oct 201984228Highwire
Nov 201993422Highwire
Dec 201952411Highwire
Jan 2020133522Highwire
Feb 202064320Highwire
Mar 202093117Highwire
Apr 2020103526Highwire
May 202052134Highwire
Jun 202032219Highwire
Jul 202022722Highwire
Aug 20202179Highwire
Sep 2020182164Highwire
Oct 202092419Highwire
Nov 2020142827Highwire
Dec 2020242731Highwire
Jan 202122229Highwire
Feb 202171436Highwire
Mar 2021102222Highwire
Apr 2021122120Highwire
May 202141619Highwire
Jun 2021102125Highwire
Jul 202192535Highwire
Aug 2021122825Highwire
Sep 202192824Highwire
Oct 2021132945Highwire
Nov 202182641Highwire
Dec 2021113228Highwire
Jan 202231914Highwire
Feb 202222632Highwire
Mar 202242139Highwire
Apr 2022102112Highwire
May 202261517Highwire
Jun 202291714Highwire
Jul 202231312Highwire
Aug 202261311Highwire
Sep 202275819Highwire
Oct 202231718Highwire
Nov 202252826Highwire
Dec 2022498Highwire
Jan 202382024Highwire
Feb 202382723Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles